questionsmedicales.fr
Cellules
Cellules cultivées
Cellules cancéreuses en culture
Lignée cellulaire tumorale
Cellules THP-1
Cellules THP-1 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules THP-1 : Questions médicales les plus fréquentes",
"headline": "Cellules THP-1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules THP-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-26",
"dateModified": "2025-03-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules THP-1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lignée cellulaire tumorale",
"url": "https://questionsmedicales.fr/mesh/D045744",
"about": {
"@type": "MedicalCondition",
"name": "Lignée cellulaire tumorale",
"code": {
"@type": "MedicalCode",
"code": "D045744",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.251.860.180"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules THP-1",
"alternateName": "THP-1 Cells",
"code": {
"@type": "MedicalCode",
"code": "D000074084",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Terumasa Ikeda",
"url": "https://questionsmedicales.fr/author/Terumasa%20Ikeda",
"affiliation": {
"@type": "Organization",
"name": "2 Institute for Molecular Virology, Minneapolis, MN 55455, USA."
}
},
{
"@type": "Person",
"name": "Michael A Carpenter",
"url": "https://questionsmedicales.fr/author/Michael%20A%20Carpenter",
"affiliation": {
"@type": "Organization",
"name": "3 Center for Genome Engineering, Minneapolis, MN 55455, USA."
}
},
{
"@type": "Person",
"name": "William L Brown",
"url": "https://questionsmedicales.fr/author/William%20L%20Brown",
"affiliation": {
"@type": "Organization",
"name": "4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA."
}
},
{
"@type": "Person",
"name": "Reuben S Harris",
"url": "https://questionsmedicales.fr/author/Reuben%20S%20Harris",
"affiliation": {
"@type": "Organization",
"name": "3 Center for Genome Engineering, Minneapolis, MN 55455, USA."
}
},
{
"@type": "Person",
"name": "Valentina Galbiati",
"url": "https://questionsmedicales.fr/author/Valentina%20Galbiati",
"affiliation": {
"@type": "Organization",
"name": "Università Degli Studi di Milano, Laboratory of Toxicology, Dipartimento di Scienze Politiche ed Ambientali, Milan, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes.",
"datePublished": "2023-08-30",
"url": "https://questionsmedicales.fr/article/37657738",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.diabet.2023.101470"
}
},
{
"@type": "ScholarlyArticle",
"name": "Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma.",
"datePublished": "2023-08-27",
"url": "https://questionsmedicales.fr/article/37777383",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clml.2023.08.017"
}
},
{
"@type": "ScholarlyArticle",
"name": "AMPAR receptor inhibitors suppress proliferation of human small cell lung cancer cell lines.",
"datePublished": "2023-08-22",
"url": "https://questionsmedicales.fr/article/37605807",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1759-7714.15075"
}
},
{
"@type": "ScholarlyArticle",
"name": "Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.",
"datePublished": "2023-08-14",
"url": "https://questionsmedicales.fr/article/37578563",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00018-023-04900-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ceramide as an endothelial cell surface receptor and a lung-specific lipid vascular target for circulating ligands.",
"datePublished": "2023-08-14",
"url": "https://questionsmedicales.fr/article/37579172",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1073/pnas.2220269120"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules cultivées",
"item": "https://questionsmedicales.fr/mesh/D002478"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cellules cancéreuses en culture",
"item": "https://questionsmedicales.fr/mesh/D014407"
},
{
"@type": "ListItem",
"position": 5,
"name": "Lignée cellulaire tumorale",
"item": "https://questionsmedicales.fr/mesh/D045744"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cellules THP-1",
"item": "https://questionsmedicales.fr/mesh/D000074084"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules THP-1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules THP-1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules THP-1",
"description": "Comment identifier les cellules THP-1 en laboratoire ?\nQuels tests sont utilisés pour caractériser les cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être contaminées ?\nQuelle est la source des cellules THP-1 ?\nLes cellules THP-1 sont-elles sensibles à des médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=ErbB+Receptors&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules THP-1",
"description": "Quels sont les marqueurs d'activation des cellules THP-1 ?\nLes cellules THP-1 montrent-elles des signes d'inflammation ?\nComment les cellules THP-1 réagissent-elles aux pathogènes ?\nLes cellules THP-1 peuvent-elles se différencier ?\nQuels effets ont les cytokines sur les cellules THP-1 ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=ErbB+Receptors&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules THP-1",
"description": "Comment prévenir la contamination des cellules THP-1 ?\nQuelles conditions de culture sont idéales pour les cellules THP-1 ?\nLes cellules THP-1 nécessitent-elles des soins particuliers ?\nComment assurer la viabilité des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être cryogénisées ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=ErbB+Receptors&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules THP-1",
"description": "Comment les cellules THP-1 sont-elles utilisées en recherche ?\nPeut-on modifier génétiquement les cellules THP-1 ?\nQuels traitements sont testés sur les cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être utilisées pour des tests de toxicité ?\nComment les cellules THP-1 aident-elles à comprendre les maladies ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=ErbB+Receptors&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules THP-1",
"description": "Quelles complications peuvent survenir lors de l'utilisation des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles induire des réponses immunitaires indésirables ?\nQuels risques sont associés à la manipulation des cellules THP-1 ?\nLes cellules THP-1 peuvent-elles être affectées par des agents externes ?\nComment minimiser les complications lors des expériences avec THP-1 ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=ErbB+Receptors&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules THP-1",
"description": "Quels facteurs influencent la croissance des cellules THP-1 ?\nLes cellules THP-1 sont-elles sensibles à des agents environnementaux ?\nQuels traitements peuvent affecter les cellules THP-1 ?\nLes cellules THP-1 sont-elles affectées par le stress oxydatif ?\nQuels facteurs génétiques influencent les cellules THP-1 ?",
"url": "https://questionsmedicales.fr/mesh/D000074084?mesh_terms=ErbB+Receptors&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les cellules THP-1 en laboratoire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules THP-1 sont identifiées par leur morphologie et leur expression de marqueurs spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour caractériser les cellules THP-1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la cytométrie en flux et l'immunofluorescence sont utilisés."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles être contaminées ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comme toutes les lignées cellulaires, elles peuvent être contaminées par des bactéries ou des mycoplasmes."
}
},
{
"@type": "Question",
"name": "Quelle est la source des cellules THP-1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules THP-1 proviennent de la moelle osseuse d'un patient atteint de leucémie."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 sont-elles sensibles à des médicaments ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent utilisées pour tester la sensibilité à divers agents pharmacologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les marqueurs d'activation des cellules THP-1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs incluent CD14, CD11b et CD68, indiquant leur activation."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 montrent-elles des signes d'inflammation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles produisent des cytokines pro-inflammatoires lorsqu'elles sont activées."
}
},
{
"@type": "Question",
"name": "Comment les cellules THP-1 réagissent-elles aux pathogènes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles phagocytent les pathogènes et sécrètent des médiateurs inflammatoires."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles se différencier ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent se différencier en macrophages sous l'influence de certains facteurs."
}
},
{
"@type": "Question",
"name": "Quels effets ont les cytokines sur les cellules THP-1 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cytokines modulent leur activation et leur capacité à produire d'autres médiateurs."
}
},
{
"@type": "Question",
"name": "Comment prévenir la contamination des cellules THP-1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des techniques aseptiques et vérifier régulièrement la pureté cellulaire."
}
},
{
"@type": "Question",
"name": "Quelles conditions de culture sont idéales pour les cellules THP-1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles nécessitent un milieu riche en nutriments et une température contrôlée."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 nécessitent-elles des soins particuliers ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles doivent être manipulées avec précaution pour éviter le stress cellulaire."
}
},
{
"@type": "Question",
"name": "Comment assurer la viabilité des cellules THP-1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir des conditions optimales de culture et éviter les cycles de congélation-décongélation."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles être cryogénisées ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être cryogénisées pour une conservation à long terme."
}
},
{
"@type": "Question",
"name": "Comment les cellules THP-1 sont-elles utilisées en recherche ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour étudier les mécanismes immunitaires et tester des médicaments."
}
},
{
"@type": "Question",
"name": "Peut-on modifier génétiquement les cellules THP-1 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques comme CRISPR peuvent être utilisées pour modifier leur génome."
}
},
{
"@type": "Question",
"name": "Quels traitements sont testés sur les cellules THP-1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements anti-inflammatoires et anticancéreux sont souvent testés."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles être utilisées pour des tests de toxicité ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent utilisées pour évaluer la toxicité des composés chimiques."
}
},
{
"@type": "Question",
"name": "Comment les cellules THP-1 aident-elles à comprendre les maladies ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles modélisent des maladies inflammatoires et infectieuses pour étudier les mécanismes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir lors de l'utilisation des cellules THP-1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des résultats biaisés peuvent survenir si les cellules sont contaminées ou mal caractérisées."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles induire des réponses immunitaires indésirables ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent parfois produire des réponses immunitaires non spécifiques."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à la manipulation des cellules THP-1 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque principal est la contamination croisée avec d'autres lignées cellulaires."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 peuvent-elles être affectées par des agents externes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des agents comme les toxines ou les médicaments peuvent altérer leur fonction."
}
},
{
"@type": "Question",
"name": "Comment minimiser les complications lors des expériences avec THP-1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivre des protocoles stricts et effectuer des contrôles réguliers de qualité."
}
},
{
"@type": "Question",
"name": "Quels facteurs influencent la croissance des cellules THP-1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme la température, le pH et la composition du milieu influencent leur croissance."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 sont-elles sensibles à des agents environnementaux ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être affectées par des agents chimiques ou physiques dans leur environnement."
}
},
{
"@type": "Question",
"name": "Quels traitements peuvent affecter les cellules THP-1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les cytokines ou les médicaments peuvent moduler leur activité."
}
},
{
"@type": "Question",
"name": "Les cellules THP-1 sont-elles affectées par le stress oxydatif ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut altérer leur fonction et leur viabilité."
}
},
{
"@type": "Question",
"name": "Quels facteurs génétiques influencent les cellules THP-1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des variations génétiques peuvent affecter leur réponse aux stimuli immunitaires."
}
}
]
}
]
}
Glucagon-like peptide 1 (GLP-1) is a hormone of the incretin family, secreted in response to nutrient ingestion, and plays a role in metabolic homeostasis. GLP-1 receptor agonist has a peripheral and ...
The inexpensive and readily available biomarkers for cytokine release syndrome (CRS) grading and prognosis assessment in chimeric antigen receptor (CAR)-T therapy are currently lacking. This study exa...
This cohort study included 27 patients with relapsed/refractory MM who were treated with CAR-T cells between December 2017 and October 2021. Patients were classified into 2 groups: normal ALP group (p...
Within 1 month of CAR-T cell infusion, the incidence of ALP increases was 63%. We found that ALP levels began to rise in the second week, peaked in the third and fourth weeks, and began to decline in ...
Our results suggest that the ALP levels after CAR-T therapy could serve as a suitable biomarker for monitoring CAR-T cell proliferation, CRS grading, and prognosis in patients with MM....
Small cell lung cancer (SCLC) is a neuroendocrine tumor with poor prognosis. Neuroendocrine tumors possess characteristics of both nerve cells and hormone-secreting cells; therefore, targeting the neu...
We performed to examine the expression of AMPAR using Western blot and immunohistochemical analysis. The antitumor effects of AMPAR antagonists on human SCLC cell lines were investigated in vitro and ...
We first examined the expression of endogenous AMPAR in six human SCLC cell lines, detecting AMPAR proteins in all of them. Next, we tested the anti-proliferative effect of two AMPAR antagonists, tala...
AMPAR may be a potential therapeutic target for SCLC....
The glucocorticoid receptor (GR) is a crucial drug target in multiple myeloma as its activation with glucocorticoids effectively triggers myeloma cell death. However, as high-dose glucocorticoids are ...
The vascular endothelium from individual organs is functionally specialized, and it displays a unique set of accessible molecular targets. These serve as endothelial cell receptors to affinity ligands...
Lethal prostate cancer (PCa) is characterized by the presence of metastases and development of resistance to therapies. Metastases form in a multi-step process enabled by dynamic cytoskeleton remodeli...
Fibroblast growth factor receptors (FGFRs) are a family of cell surface receptors that bind to fibroblast growth factor (FGF) and mediate various cellular functions (translocating proteins, tissue rep...
Pancreatic ductal adenocarcinoma (PDA) is a pernicious disease characterized by an immunosuppressive milieu that is unresponsive to current immunotherapies. Interleukin-1 receptor antagonist (IL-1Ra) ...
Through analyzing clinical dataset and examining the pathological tumor tissues and serum samples, we have demonstrated that IL-1Ra expression is elevated in human PDA and positively associated with m...
Our findings illustrate the immunosuppressive properties of the natural anti-inflammatory cytokine IL-1Ra, and provide a rationale for considering IL-1Ra-targeted therapies in the treatment of PDA....
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are potent antihyperglycemic agents with beneficial effects on weight, cardiovascular, and renal outcomes. Physicians lack guidance as to which pa...
Adults with type 2 diabetes treated with insulin who had a GLP-1 RA added to their regimen were evaluated retrospectively. Baseline parameters and outcomes at 3, 6, and 12 months were collected....
Among the 81 patients included, there was a mean reduction in hemoglobin A1C of 0.94% (SD, 0.26;...
The addition of a GLP-1 RA reduced HbA1C, weight, and insulin requirements in this cohort of patients with type 2 diabetes on insulin. BMI, baseline insulin dose, and diabetes duration did not predict...
In recent years, several systemic therapies have been introduced for metastatic hormone-sensitive prostate cancer, including androgen deprivation therapy (ADT) combined with docetaxel (Doc) and/or new...